Hepsen, SemaKeskin, Dilek BadayCakal, Erman2025-01-212025-01-2120231751-99181878-0210https://doi.org/10.1016/j.pcd.2022.11.004https://hdl.handle.net/20.500.12587/25541Aims: Neuropathic pain is associated with several clinical conditions, including anxiety, depression, sleep dis-orders, and decreased quality of life; however, less evaluated in prediabetes. This study aims to assess neuro-pathic pain through validated diagnostic tools in prediabetes.Methods: One hundred and seventy-two patients with prediabetes and 170 controls were included in this cross-sectional study. The Leeds Assessment of Neuropathic Symptoms and Signs (LANSS) Pain Scale and Douleur Neuropathique 4 Questions (DN4) were used to evaluate neuropathic pain. The Visual Analog Scale (VAS) was used to estimate pain intensity.Results: Twenty-three (13.4%) and 12 (7%) patients with prediabetes were diagnosed with neuropathic pain using DN4 and LANSS questionnaires, respectively. Neuropathic pain rates of the patients were higher than controls with two pain scales (p < 0.001). VAS scores were higher in prediabetes group than in controls (p = 0.021). LANSS, DN4, and VAS scores were positively correlated with HbA1c level (r = 0.184, p = 0.016; r = 0.180, p = 0.018; r = 0.188, p = 0.014, respectively). LANNS and DN4 scores were higher in female patients than in males (p < 0.001).Conclusions: Neuropathic pain was increased in prediabetes by DN4 and LANNS questionnaires. An appropriate diagnosis of neuropathic pain in prediabetes may prevent patients from different pain-related clinical conditions.eninfo:eu-repo/semantics/closedAccessDN4; LANNS; Neuropathic pain; Prediabetes; VASArticle171333710.1016/j.pcd.2022.11.0042-s2.0-8514252790136435735Q2WOS:000963646000001Q1